You just read:

Indivior PLC Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder

News provided by

Indivior PLC

Jul 31, 2017, 08:30 ET